When the IKK inhibitor BMS-345541 was used in combination with BTZ, the survival of CD34(+) AML cells was reduced [26], which suggest that NF-kB may be involved in BTZ resistance in AML. The gene discussed is NFKB1; the disease is acute myeloid leukemia.